Skip to main content

Table 5 Logistic regression for the therapeutic indicator of global status: ΔCDR-SB

From: Cilostazol as an add-on therapy for patients with Alzheimer’s disease in Taiwan: a case control study

 

odds ratio

95% CI

p-value

Age, years (mean ± SD)

1.01

0.88–1.15

0.920

Education, years (mean ± SD)

1.02

0.88–1.21

0.778

Gender, female (%)

3.33

0.68–18.62

0.146

1st CDR-SB

0.90

0.63–1.28

0.573

1st MMSE

1.00

0.82–1.22

0.962

Cilostazol use

0.51

0.12–1.99

0.331

ApoE ε4(+),n (%)

0.39

0.07–1.92

0.248

  1. Odds ratios are based on comparing odds of poor (CDR_SB > 0) versus favorable (ΔCDR_SB ≤ 0) therapeutic indicators of global status
  2. MMSE Mini-Mental Status Examination, CDR_SB Clinical Dementia Rating Sum of Boxes scale, ApoE apolipoprotein E, ΔCDR_SB: 2nd CDR_SB–1st CDR_SB
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us